Research Article
Subthalamic hGAD65 Gene Therapy and Striatum TH Gene Transfer in a Parkinson’s Disease Rat Model
Table 2
Concentration of DA in the striatum (nmol/L, ).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statistical significance (**, ##) in the concentrations of DA in the striatum between the rAAV2-hGAD65-treated group and the TH-treated group or the combination-treated group, at 4, 8, and 16 weeks after treatment (, ). The DA level of rAAV2-hGAD65 group was similar to that of three control groups (fibroblasts, rAAV2 vector, and PBS groups at 4, 8, and 16 week after treatment, respectively (, ). Fibroblasts (TH), fibroblasts transferred by rAd-TH; rAAV2-hGAD65, recombinant adeno-associated virus particles, containing human glutamic acid decarboxylase 2 gene; combination, rAAV2-hGAD65 + fibroblasts (TH), fibroblasts, primary cultrued fibroblasts, rAAV2 vector, recombinant AAV2 particles, PBS, pH = 7.2, 0.1 M. |